These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 22206873)
1. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis. Gomez-Fernandez C; Garden BC; Wu S; Feldman DR; Lacouture ME Eur J Cancer; 2012 Feb; 48(3):340-6. PubMed ID: 22206873 [TBL] [Abstract][Full Text] [Related]
2. Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials. Shameem R; Lacouture M; Wu S Acta Oncol; 2015 Jan; 54(1):124-32. PubMed ID: 24914484 [TBL] [Abstract][Full Text] [Related]
3. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients. Shameem R; Lacouture M; Wu S Cancer Invest; 2015 Mar; 33(3):70-7. PubMed ID: 25635371 [TBL] [Abstract][Full Text] [Related]
4. Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis. Ramirez-Fort MK; Case EC; Rosen AC; Cerci FB; Wu S; Lacouture ME Am J Clin Oncol; 2014 Jun; 37(3):266-71. PubMed ID: 23241507 [TBL] [Abstract][Full Text] [Related]
5. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis. Xu J; Tian D Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709 [TBL] [Abstract][Full Text] [Related]
6. Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Su X; Lacouture ME; Jia Y; Wu S Oncology; 2009; 77(2):124-33. PubMed ID: 19622903 [TBL] [Abstract][Full Text] [Related]
7. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. Minkis K; Garden BC; Wu S; Pulitzer MP; Lacouture ME J Am Acad Dermatol; 2013 Sep; 69(3):e121-8. PubMed ID: 23357570 [TBL] [Abstract][Full Text] [Related]
8. Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials. Peng L; Zhou Y; Ye X; Zhao Q Tumour Biol; 2015 Feb; 36(2):643-54. PubMed ID: 25281033 [TBL] [Abstract][Full Text] [Related]
9. The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. Garden BC; Wu S; Lacouture ME J Am Acad Dermatol; 2012 Sep; 67(3):400-8. PubMed ID: 22088429 [TBL] [Abstract][Full Text] [Related]
10. Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis. Jia Y; Lacouture ME; Su X; Wu S J Support Oncol; 2009; 7(6):211-7. PubMed ID: 20380328 [TBL] [Abstract][Full Text] [Related]
11. Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis. Wei F; Shin D; Cai X Int J Clin Oncol; 2018 Jun; 23(3):443-451. PubMed ID: 29289981 [TBL] [Abstract][Full Text] [Related]
12. Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients. Lo Muzio L; Arena C; Troiano G; Villa A Oral Dis; 2018 Mar; 24(1-2):144-171. PubMed ID: 29480626 [TBL] [Abstract][Full Text] [Related]
13. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Chu D; Lacouture ME; Weiner E; Wu S Clin Genitourin Cancer; 2009 Jan; 7(1):11-9. PubMed ID: 19213662 [TBL] [Abstract][Full Text] [Related]
14. Risk of anemia attributable to everolimus in patients with cancer: a meta-analysis of randomized controlled trials. Shameem R; Hamid MS; Wu S Anticancer Res; 2015 Apr; 35(4):2333-40. PubMed ID: 25862897 [TBL] [Abstract][Full Text] [Related]
15. Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis. Abdel-Rahman O; Fouad M Expert Rev Anticancer Ther; 2015; 15(7):847-58. PubMed ID: 25994247 [TBL] [Abstract][Full Text] [Related]
16. Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. Drucker AM; Wu S; Dang CT; Lacouture ME Breast Cancer Res Treat; 2012 Sep; 135(2):347-54. PubMed ID: 22782294 [TBL] [Abstract][Full Text] [Related]
17. Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis. Lasheen S; Shohdy KS; Kassem L; Abdel-Rahman O Expert Rev Anticancer Ther; 2017 Sep; 17(9):851-856. PubMed ID: 28699811 [TBL] [Abstract][Full Text] [Related]
18. Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis. Nardone B; Wu S; Garden BC; West DP; Reich LM; Lacouture ME Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):424-9. PubMed ID: 23769670 [TBL] [Abstract][Full Text] [Related]
19. Risk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis. Zhang X; Ran YG; Wang KJ Future Oncol; 2016 Dec; 12(23):2741-2753. PubMed ID: 27522860 [TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of dermatological toxicities associated with sorafenib. Zhang L; Zhou Q; Ma L; Wu Z; Wang Y Clin Exp Dermatol; 2011 Jun; 36(4):344-50. PubMed ID: 21507035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]